Share on LinkedInShare on LinkedIn

ARTICLE · 15 NOVEMBER 2024

Is it Obvious? Sandoz v Bayer and a Patent's Inventive Step

Piper Alderman
Piper Alderman
Contributor
Piper Alderman

Piper Alderman

Helping shape the future of business in Australia with practical, commercial and cutting-edge legal...

View firm profile
Explore more from Piper Alderman

Clarifies the test for obviousness in relation to the development of pharmaceutical drugs.

AustraliaIntellectual Property

The validity of a patent relies, amongst other things, on the claimed invention involving an inventive step. This requires the claimed invention to not be obvious to a person skilled in the relevant art, in light of the common general knowledge. A recent Full Court decision clarifies the test for obviousness in relation to the development of pharmaceutical drugs.

Background Facts

Bayer Australia Limited (Bayer Australia) is the exclusive licensee of the following patents in Australia:

  • Australian Patent No 2004305226, entitled "Method for the production of a solid, orally applicable pharmaceutical composition" with a priority date of 27 November 2003; and
  • Australian Patent No 2006208613, entitled "Prevention and treatment of thromboembolic disorders" with a priority date of 31 January 2005.1

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from